256 related articles for article (PubMed ID: 28089149)
1. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.
Farhan S; Clare RM; Jarai R; Giugliano RP; Lokhnygina Y; Harrington RA; Kristin Newby L; Huber K
Int J Cardiol; 2017 Apr; 232():264-270. PubMed ID: 28089149
[TBL] [Abstract][Full Text] [Related]
2. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK
Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952
[TBL] [Abstract][Full Text] [Related]
3. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
[TBL] [Abstract][Full Text] [Related]
4. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
Lopes RD; White JA; Tricoci P; White HD; Armstrong PW; Braunwald E; Giugliano RP; Harrington RA; Lewis BS; Brogan GX; Gibson CM; Califf RM; Newby LK
Int J Cardiol; 2013 Sep; 167(6):2580-7. PubMed ID: 22795720
[TBL] [Abstract][Full Text] [Related]
5. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.
Lindholm D; James SK; Bertilsson M; Becker RC; Cannon CP; Giannitsis E; Harrington RA; Himmelmann A; Kontny F; Siegbahn A; Steg PG; Storey RF; Velders MA; Weaver WD; Wallentin L;
Clin Chem; 2017 Feb; 63(2):573-584. PubMed ID: 27932413
[TBL] [Abstract][Full Text] [Related]
7. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM;
JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880
[TBL] [Abstract][Full Text] [Related]
8. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
Kunadian V; Giugliano RP; Newby LK; Zorkun C; Guo J; Bagai A; Montalescot G; Braunwald E; Califf RM; Van de Werf F; Armstrong PW; Harrington R; Gibson CM
Am J Cardiol; 2014 Apr; 113(8):1297-305. PubMed ID: 24607027
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.
Eggers KM; Lagerqvist B; Venge P; Wallentin L; Lindahl B
J Am Coll Cardiol; 2009 Jul; 54(4):357-64. PubMed ID: 19608034
[TBL] [Abstract][Full Text] [Related]
10. The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study.
He WF; Jiang L; Chen YY; Liu YH; Chen PY; Duan CY; Zeng LH; Fan HL; Wei XB; Guo W; Chen W; Li J; Li WS; Guo ZQ; Liu ZK; Tan N; Chen JY; He PC
BMC Cardiovasc Disord; 2021 Apr; 21(1):202. PubMed ID: 33882836
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.
Buchner S; Debl K; Barlage S; Griese D; Fredersdorf S; Jeron A; Lubnow M; Müller T; Muders F; Holmer S; Riegger GA; Luchner A
Clin Chem Lab Med; 2010 Jun; 48(6):875-81. PubMed ID: 20441480
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of NT-proBNP for 30-day mortality in patients with non-ST-elevation acute coronary syndromes: a comparison with the GRACE and TIMI risk scores.
Schellings DA; Adiyaman A; Dambrink JE; Gosselink AM; Kedhi E; Roolvink V; Ottervanger JP; Van't Hof AW
Vasc Health Risk Manag; 2016; 12():471-476. PubMed ID: 27920547
[TBL] [Abstract][Full Text] [Related]
13. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
[TBL] [Abstract][Full Text] [Related]
14. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.
Toleva O; Westerhout CM; Senaratne MP; Bode C; Lindroos M; Sulimov VA; Montalescot G; Newby LK; Giugliano RP; Van de Werf F; Armstrong PW
Catheter Cardiovasc Interv; 2014 Nov; 84(6):934-42. PubMed ID: 24976083
[TBL] [Abstract][Full Text] [Related]
15. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
[TBL] [Abstract][Full Text] [Related]
16. NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes.
Zdravkovic V; Mladenovic V; Colic M; Bankovic D; Lazic Z; Petrovic M; Simic I; Knezevic S; Pantovic S; Djukic A; Zdravkovic N
Kardiol Pol; 2013; 71(5):472-9. PubMed ID: 23788087
[TBL] [Abstract][Full Text] [Related]
17. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between plasma N-terminal pro-brain natriuretic peptide and GRACE risk stratification in non-ST-segment elevation acute coronary syndrome].
Liu WX; Zhao H
Zhonghua Xin Xue Guan Bing Za Zhi; 2012 May; 40(5):373-7. PubMed ID: 22883085
[TBL] [Abstract][Full Text] [Related]
19. A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes.
Ndrepepa G; Braun S; Mehilli J; Niemöller K; Schömig A; Kastrati A
Clin Res Cardiol; 2007 Jan; 96(1):30-7. PubMed ID: 17066344
[TBL] [Abstract][Full Text] [Related]
20. Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
Schellings DA; Adiyaman A; Giannitsis E; Hamm C; Suryapranata H; Ten Berg JM; Hoorntje JC; Van't Hof AW
J Am Heart Assoc; 2014 Nov; 3(6):e001089. PubMed ID: 25389283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
